Alopecia following initiation of lisdexamfetamine in a pediatric patient.

To the Editor: Lisdexamfetamine, a prodrug of dextroamphetamine, is indicated for the treatment of attentiondeficit/hyperactivity disorder (ADHD) in both pediatric and adult patients. One of the advantages cited includes an inactive prodrug status. The side effect profile is consistent with other stimulants. In children aged 6–12 years old, the most common adverse reactions by frequency are decreased appetite, insomnia, upper abdominal pain, and irritability. Alopecia or diffuse hair loss has not been reported in the manufacturer’s information or with postmarketing analysis of adverse drug effects reported to poison centers. As confirmed by a PubMed literature search utilizing the search terms alopecia and lisdexamfetamine, we report the first case of diffuse thinning hair loss secondary to lisdexamfetamine use in a pediatric patient.